Log In Get Started
Press Releases July 21, 2026 09:00 AM

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

OKYO Pharma to Present Pipeline Progress at H.C. Wainwright Ophthalmology Conference

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
OKYO

OKYO Pharma Limited announced its participation in the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference, where its CEO and CMO will present updates on its clinical-stage programs targeting neuropathic corneal pain (NCP) and anterior segment eye diseases. The company plans to initiate a global Phase 3 pivotal clinical trial for urcosimod, a potential single-dose treatment for NCP, in the second half of 2026.

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference
OKYO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • OKYO Pharma is advancing its clinical-stage therapies focused on neuropathic corneal pain and anterior segment eye diseases.
  • The company will present updates at a prominent ophthalmology virtual conference on July 22, 2026.
  • Plans to initiate a global Phase 3 trial for urcosimod as a single-dose treatment for NCP later this year.
  • Impacted sectors include biotechnology, pharmaceuticals, and healthcare, particularly ophthalmology drug development.

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.

Details of the event are as follows:

Presenter: Robert J. Dempsey, Chief Executive Officer, Flavio Mantelli MD, PhD, Chief Medical Officer
Date/Time: Wednesday, July 22, 12:30 PM ET
Location: Virtual
Register to Attend: H.C. Wainwright Registration

About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.

For further information, please visit www.okyopharma.com.

For further inquiries:

OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com


Risks

  • Clinical trial initiation and enrollment may face delays or complications impacting the development timeline.
  • Efficacy and safety outcomes of the Phase 3 trial for urcosimod remain uncertain and could impact regulatory approval.
  • Market competition and regulatory hurdles in ophthalmology and biopharmaceutical sectors could pose challenges to commercial success.

More from Press Releases

Ohio Valley Conference and Gray Media Again Partner to Bring Collegiate Sporting Events to Free Over-the-Air Television Viewers Sep 21, 2026 Generative Engine Optimization Emerges as the Holiday Season's Fastest-Growing Service Sep 21, 2026 Davis Commodities Limited Announces Nasdaq Delisting and Continued Quotation on OTC Markets Sep 21, 2026 Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum Sep 21, 2026 FingerMotion Advances 99 MW Alberta Program with Second Campus: Binding Letter of Intent to Acquire Powered Land in Hanna Sep 21, 2026